| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1013528465 |
| P356 | DOI | 10.1007/S00210-014-0967-3 |
| P932 | PMC publication ID | 4019832 |
| P698 | PubMed publication ID | 24643470 |
| P5875 | ResearchGate publication ID | 260916184 |
| P50 | author | Helmout Modjtahedi | Q55475854 |
| Martin Christian Michel | Q57055217 | ||
| P2093 | author name string | Flavio Solca | |
| Byoung Chul Cho | |||
| P2860 | cites work | Computational Studies of Epidermal Growth Factor Receptor: Docking Reliability, Three-Dimensional Quantitative Structure−Activity Relationship Analysis, and Virtual Screening Studies | Q59171683 |
| The primary structure of epidermal growth factor | Q69387018 | ||
| Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal | Q79368389 | ||
| Oncogenic ERBB3 mutations in human cancers | Q24293022 | ||
| An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor | Q24293598 | ||
| EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib | Q24606177 | ||
| ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation | Q24621754 | ||
| The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP | Q24649549 | ||
| BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models | Q24649935 | ||
| ErbB receptors: from oncogenes to targeted cancer therapies | Q24683709 | ||
| Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain | Q24794765 | ||
| Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker | Q27681964 | ||
| EGFR mutation and resistance of non-small-cell lung cancer to gefitinib | Q27824829 | ||
| HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy | Q27851461 | ||
| Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. | Q27851483 | ||
| Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer | Q27851549 | ||
| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors | Q27851633 | ||
| Activating HER2 mutations in HER2 gene amplification negative breast cancer | Q27851987 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors | Q28207289 | ||
| PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR | Q28240702 | ||
| The ErbB/HER family of protein-tyrosine kinases and cancer | Q28302611 | ||
| Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling | Q28472663 | ||
| Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells | Q28481370 | ||
| Comprehensive analysis of kinase inhibitor selectivity | Q29616719 | ||
| EGFR antagonists in cancer treatment | Q29616740 | ||
| Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation | Q33526744 | ||
| Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors | Q33769838 | ||
| Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor | Q33810574 | ||
| ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling | Q33886341 | ||
| EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications | Q33963199 | ||
| Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. | Q33964848 | ||
| Irreversible EGFR inhibitor EKB-569 targets low-LET γ-radiation-triggered rel orchestration and potentiates cell death in squamous cell carcinoma | Q34126513 | ||
| Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. | Q34205052 | ||
| Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. | Q34569071 | ||
| Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. | Q35271691 | ||
| Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells | Q35623056 | ||
| ErbB receptors: directing key signaling networks throughout life | Q35639126 | ||
| Subtype and pathway specific responses to anticancer compounds in breast cancer | Q35779241 | ||
| Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells | Q35835273 | ||
| Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression. | Q35889217 | ||
| Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer | Q35977527 | ||
| Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. | Q36185012 | ||
| Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. | Q36221780 | ||
| HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation | Q36322762 | ||
| Personalized medicine and treatment approaches in non-small-cell lung carcinoma | Q36441548 | ||
| Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer | Q36482542 | ||
| Noncovalent wild-type-sparing inhibitors of EGFR T790M | Q36622817 | ||
| Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. | Q36673751 | ||
| Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins | Q36726112 | ||
| The role of the EGFR signaling in tumor microenvironment. | Q36951215 | ||
| Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma | Q37000611 | ||
| Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer? | Q47692335 | ||
| Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation. | Q47943383 | ||
| Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. | Q53316003 | ||
| EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. | Q54564313 | ||
| Genetic and chemical targeting of epithelial-restricted with serine box reduces EGF receptor and potentiates the efficacy of afatinib | Q37101367 | ||
| Acquired resistance to tyrosine kinase inhibitors during cancer therapy | Q37104243 | ||
| Structure and clinical relevance of the epidermal growth factor receptor in human cancer | Q37122918 | ||
| Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. | Q37141350 | ||
| Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer | Q37355762 | ||
| Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer | Q37363050 | ||
| Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. | Q37379113 | ||
| HER-2/neu oncogene amplification and expression in breast and ovarian cancers | Q37605489 | ||
| Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer | Q37653443 | ||
| Potential of ErbB4 antibodies for cancer therapy. | Q37658764 | ||
| The receptor for EGF and its ligands - expression, prognostic value and target for therapy in cancer (review). | Q37874958 | ||
| Irreversible protein kinase inhibitors: balancing the benefits and risks | Q38012518 | ||
| Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancer. | Q38015157 | ||
| Prognostic significance and targeting of HER family in colorectal cancer | Q38070499 | ||
| Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. | Q38080898 | ||
| Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling. | Q39122768 | ||
| Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model | Q39188098 | ||
| Genotype-selective combination therapies for melanoma identified by high-throughput drug screening | Q39226193 | ||
| Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations. | Q39250868 | ||
| Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck | Q39297048 | ||
| Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation | Q39297840 | ||
| Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. | Q39306353 | ||
| SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo. | Q39399335 | ||
| Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. | Q39399655 | ||
| The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor | Q39415296 | ||
| The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines | Q39422598 | ||
| Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer | Q39434209 | ||
| Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models | Q39512157 | ||
| Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members | Q39535457 | ||
| Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer | Q39595342 | ||
| The effect of acquired cisplatin resistance on sensitivity to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer cells | Q39614263 | ||
| Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapy | Q39656288 | ||
| Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor | Q39695840 | ||
| Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. | Q40133869 | ||
| Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. | Q40449400 | ||
| Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients | Q42043613 | ||
| Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer | Q43606249 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P921 | main subject | cancer | Q12078 |
| enzyme | Q8047 | ||
| heterocyclic compound | Q193430 | ||
| membrane protein | Q423042 | ||
| neoplasm | Q1216998 | ||
| cell surface receptor | Q2476074 | ||
| antineoplastic | Q2853144 | ||
| P304 | page(s) | 505-521 | |
| P577 | publication date | 2014-03-19 | |
| 2014-06-01 | |||
| P1433 | published in | Naunyn-Schmiedeberg's Archives of Pharmacology | Q1468251 |
| P1476 | title | A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer | |
| P478 | volume | 387 |
| Q36571455 | Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition. |
| Q53402902 | Adverse kidney effects of epidermal growth factor receptor inhibitors. |
| Q33649260 | Afatinib ameliorates osteoclast differentiation and function through downregulation of RANK signaling pathways. |
| Q27853078 | Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. |
| Q26749005 | Afatinib in Non-Small Cell Lung Cancer |
| Q52655265 | Afatinib in advanced NSCLC: a profile of its use. |
| Q33591405 | Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells |
| Q60050170 | Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway |
| Q38646686 | Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress |
| Q39016290 | Afatinib: A Review in Advanced Non-Small Cell Lung Cancer |
| Q54979771 | Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma. |
| Q57818008 | Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma |
| Q37008862 | Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue |
| Q39156722 | Biological determinants of radioresistance and their remediation in pancreatic cancer |
| Q38262804 | Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma. |
| Q37650711 | Clinical Pharmacokinetics and Pharmacodynamics of Afatinib |
| Q64055605 | Clinical development of targeted and immune based anti-cancer therapies |
| Q60193666 | Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells. |
| Q71098757 | Design and synthesis of novel 6-substituted quinazoline-2-thiols |
| Q37004934 | Digital Gene Expression Analysis of Populus simonii × P. nigra Pollen Germination and Tube Growth |
| Q36095074 | Down-regulation of neutrophil gelatinase-associated lipocalin in head and neck squamous cell carcinoma correlated with tumorigenesis, not with metastasis |
| Q43604978 | Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France |
| Q89834325 | How Different Substitution Positions of F, Cl Atoms in Benzene Ring of 5-Methylpyrimidine Pyridine Derivatives Affect the Inhibition Ability of EGFRL858R/T790M/C797S Inhibitors: A Molecular Dynamics Simulation Study |
| Q38969795 | Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells |
| Q91726663 | Inhibition of cisplatin-resistant head and neck squamous cell carcinoma by combination of Afatinib with PD0325901, a MEK inhibitor |
| Q31028700 | Longitudinal trends and subgroup analysis in publication patterns for preclinical data of newly approved drugs |
| Q54166640 | Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer. |
| Q50064748 | Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer |
| Q41021890 | Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets |
| Q89278505 | Naunyn-Schmiedeberg's Archives of Pharmacology under new editorship: change and continuity |
| Q35807946 | Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib |
| Q37702126 | Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma |
| Q28076506 | Opportunities and Challenges for Drug Development: Public-Private Partnerships, Adaptive Designs and Big Data |
| Q52591096 | Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer. |
| Q50026716 | Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. |
| Q38411081 | Preclinical research strategies for newly approved drugs as reflected in early publication patterns |
| Q38848784 | Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment. |
| Q90371930 | Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System |
| Q104111327 | Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis |
| Q40862682 | Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer. |
| Q91143046 | Small-molecule targeting of brachyury transcription factor addiction in chordoma |
| Q26745776 | Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far |
| Q33822560 | Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines |
| Q47138128 | The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations. |
Search more.